ASH 2018: Dec 1-4

Please join our staff as we participate or present in the following presentations at the 2018 ASH Annual Meeting

Friday Satellite Symposium
Friday, Nov. 30

Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies
Chair and Speaker: Matt Kalaycio, MD
7–11 a.m.
Hyatt, Coronado Ballroom A-C

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

What’s New in VTE? Evaluating the Latest Evidence and Grades of Recommendation
Chair: Alok Khorana, MD
12:30–4:30 p.m.
Hyatt, Coronado Ballroom A-C

Friday Scientific Workshops
Friday, Nov. 30
Ethical Discussion Surrounding Testing
Panelist: Hetty E. Carraway, MD, MBA
4:30–5:15 p.m.
San Diego Convention Center, Room 28D

Special Scientific Symposium
Monday, Dec. 3
Special Symposium on the Basic Science of Hemostasis and Thrombosis
Co-Chair: Keith R. McCrae, MD
4:30–6:30 p.m.
San Diego Convention Center, Room 30D

Best of ASH in Hemostasis and Thrombosis 2
Speaker: Keith R. McCrae, MD
4:30–6:30 p.m.
San Diego Convention Center, Room 30D

Education Programs
2018 Education Program Co-Chair: Mikkael A. Sekeres, MD

Sessions on Malignant Hematology
Saturday, Dec. 1
The Molecular Maelstrom of Myelodysplastic Syndromes (MDS): The MDS Genomics-Prognosis Symbiosis
Speaker: Aziz Nazha, MD
4:00–5:30 p.m.
San Diego Convention Center, Room 6A

Sunday, Dec. 2
Reining in Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation:
Current Approaches to Prevent and Treat GVHD Following Allogeneic Stem Cell Transplantation
Speaker: Betty K. Hamilton, MD
7:30–9:00 a.m.
Manchester Grand Hyatt San Diego, Grand Hall D

The Molecular Maelstrom of Myelodysplastic Syndromes (MDS): The MDS Genomics-Prognosis Symbiosis
Speaker: Aziz Nazha, MD
9:30–11:00 a.m.
San Diego Convention Center, Room 6A

Using Genomics to Risk Stratify and Treat Kids: Ethical Conundrums in Pediatric Genomics
Speaker: Eric Kodish, MD
9:30–11:00 a.m.
Marriott Marquis San Diego Marina, San Diego Ballroom B

Monday, Dec. 3
Using Genomics to Risk Stratify and Treat Kids: Ethical Conundrums in Pediatric Genomics
Speaker: Eric Kodish, MD
7:00–8:30 a.m.
Marriott Marquis San Diego Marina, Pacific Ballroom 21

Reining in Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation:
Current Approaches to Prevent and Treat GVHD Following Allogeneic Stem Cell Transplantation
Speaker: Betty K. Hamilton, MD
10:30 a.m.–Noon
Manchester Grand Hyatt San Diego, Grand Hall D

Education Spotlight Sessions
Sunday, Dec. 2
Population Risks of Developing Myeloid Malignancies
Chair: Sudipto Mukherjee, MD, PhD, MPH
4:30–6:00 p.m.
San Diego Convention Center, Room 11B

From Fat Man to Agent Orange and Beyond: When Myeloid Malignancies Strike
Speaker: Sudipto Mukherjee, MD, PhD, MPH
4:30–6:00 p.m.
San Diego Convention Center, Room 11B

Monday, Dec. 3
The Story Is the Story: Using Narrative Medicine to Cure Disease
Chair: Mikkael A. Sekeres, MD, MS
10:30 a.m.–Noon
San Diego Convention Center, Room 6E

Scientific Programs
Saturday, Dec. 1
Scientific Committee on Thrombosis and Vascular Biology
Microparticles and Exosomes: Ready for the Clinic?
Chair: Keith R. McCrae, MD
9:30–11:00 a.m.
San Diego Convention Center, Room 24B
Or
4:00–5:30 p.m.
San Diego Convention Center, Room 11B

Monday, Dec. 3
Special Scientific Symposia
Special Symposium on the Basic Science of Hemostasis and Thrombosis
Co-Chair: Keith R. McCrae, MD
4:30–6:30 p.m.
San Diego Convention Center, Room 30D

Best of ASH in Hemostasis and Thrombosis 2
Speaker: Keith R. McCrae, MD
4:30–6:30 p.m.
San Diego Convention Center, Room 30D

Special Interest Sessions
Friday, Nov. 30
Training Program Directors’ Workshop
Chair: Hetty E. Carraway, MD, MBA
11 a.m.–2 p.m.
Petco Park, The Auditorium

Sunday, Dec. 2
Social Media for the Hematologist: Today and in the Future
Chair: Aaron T. Gerds, MD, MS
11:15 a.m.–12:15 p.m.
San Diego Convention Center, Room 28D

Trainee Activities
Friday, Nov. 30
Blood Drops. Career 101: Early Career Planning Topics
Knocking Your Fellowship Interview out of the Park! Tips to Make Sure Your Interview Day Is a #homerun
Speaker: Hetty E. Carraway, MD, MBA
1:30–4:45 p.m.
Petco Park, Western Metal Concourse

Blood Drops. Hematology 201: A Mid-Level Clinical Topic
Identifying White Cell Disorder on the Peripheral Smear
Speaker: Anne T. Neff, MD
1:30–4:45 p.m.
Petco Park, Western Metal Concourse

Blood Drops. Wellness: Topics to Help Your Well-Being
Telling It Like It Is — Essays About Medicine
Speaker: Mikkael A. Sekeres, MD, MS
1:30–4:45 p.m.
Petco Park, Western Metal Concourse

Blood Buddies. Mentor Session 1
Adult Clinical Non-Malignant Hem
Presenter: Keith R. McCrae, MD
2:30–3:00 p.m.
Petco Park, Section 124 — The Porch

Laboratory & Translational Hem
Presenter: Keith R. McCrae, MD
2:30–3:00 p.m.
Petco Park, Section 124 — The Porch

Adult Clinical Malignant Hem
Presenter: Aziz Nazha, MD
2:30–3:00 p.m.
Petco Park, Section 124 — The Porch

Blood Buddies. Mentor Session 2
Laboratory & Translational Hem
Presenter: Keith R. McCrae, MD
3:30–4:00 p.m.
Petco Park, Section 124 — The Porch

Adult Clinical Non-Malignant Hem
Presenter: Keith R. McCrae, MD
3:30–4:00 p.m.
Petco Park, Section 124 — The Porch

Adult Clinical Malignant Hem
Presenter: Aziz Nazha, MD
3:30–4:00 p.m.
Petco Park, Section 124 — The Porch

Saturday, Dec. 1
Career-Development Lunch Sessions
Adult Clinical Malignant Hematology/BMT
Speaker: Navneet Majhail, MD
11:15 a.m.–12:15 p.m.
Hilton San Diego Bayfront, Sapphire Ballroom AB

General Sessions
Tuesday, Dec. 4
Late-Breaking Abstracts
Hematology Disease Topics & Pathways: Biological Processes
Co-Chair: Mikkael A. Sekeres, MD, MS
7:30–9:00 a.m.
San Diego Convention Center, Hall AB

Plenary Scientific Sessions
Sunday, Dec. 2
Hematology Disease Topics & Pathways: Biological, Diseases, MDS, Myeloid Malignancies
1 The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
Co-Author: Mikkael A. Sekeres, MD, MS
2–4 p.m.
San Diego Convention Center, Hall AB

Late Breaking Abstract Sessions
Tuesday, Dec 4
LBA-1 Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)
Presenter: Alok Khorana, MD
7:30 a.m.
San Diego Convention Center, Hall AB

Oral Sessions
Saturday, Dec. 1
Session 614. Acute Lymphoblastic Leukemia: Therapy, Excluding Transplantation: Improving Frontline Therapy in ALL
33 Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed by Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia
Presenter: Anjali S. Advani, MD
8 a.m.
Marriott Marquis San Diego Marina, Pacific Ballroom 20

Session 615. Acute Myeloid Leukemia: Commercially Available Therapy, Excluding Transplantation: Optimal Induction and Re-Induction Regimens for Acute Myeloid Leukemia
Moderator: Anjali S. Advani, MD
9:30–11:00 a.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom F

Session 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Outcomes with CD19 CAR T Therapy and Checkpoint Blockade in the Real-World Setting
Moderator: Brian T. Hill, MD, PhD
9:30–11:00 a.m.
Marriott Marquis San Diego Marina, Pacific Ballroom 20

91 Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real-World Experience
Co-Author: Brian T. Hill, MD, PhD
9:30 a.m.

104 Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS)
Presenter: Yasunobu Nagata
Co-Authors: Cassandra M. Hirsch; Abhinav Goyal; Hassan Awada, MD; Mohammad Fahad B. Asad; Teodora Kuzmanovic, BA; Bartlomiej P. Przychodzen; Sudipto Mukherjee, MD, PhD, MPH; Tomas Radivoyevitch, PhD; Aziz Nazha, MD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD
9:45 a.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom A

107 SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition
Co-Authors: Bartlomiej Przychodzen; Jaroslaw P. Maciejewski, MD, PhD
10:30 a.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom A

108 Novel and Significant Impact of Germline Variants Predisposed to Pathogenic Somatic Mutations and Loss of Heterozygosity (LOH) in Myelodysplastic Syndromes (MDS) and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Co-Author: Yasunobu Nagata
10:45 a.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom A

Session 802. Chemical Biology and Experimental Therapeutics: New Targeted Therapies and Drug Development
211 Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies
Presenter: Valeria Visconte, PhD
Co-Authors: Bartlomiej P. Przychodzen; Vera Adema, PhD; Cassandra M. Hirsch; Allison Noe; Rachel Toth; Christina Snider, BA; Hassan Awada, MD; Amy C Graham, BS, MS; Yvonne Parker; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Tomas Radivoyevitch; Heesun J. Rogers, MD, PhD; Daniel Lindner, MD, PhD; Richard A. Padgett; Mikkael A. Sekeres, MD, MS; James G. Phillips, PhD; Jaroslaw P. Maciejewski, MD, PhD
2 p.m.
San Diego Convention Center, Room 7B

216 A First-in-Class Inhibitor of ISWI-Mediated (ATP-Dependent) Transcription Repression Releases Terminal-Differentiation in AML Cells While Sparing Normal Hematopoiesis
Presenter: Ashwin Kishtagari, MBBS
Co-Authors: Kwok Peng Ng, PhD; Charlotte Jarman; Anand D. Tiwari, PhD; James G. Phillips, PhD; Caroline Schuerger; Babal K. Jha; Yogenthiran Saunthararajah, MD
3:15 p.m.
San Diego Convention Center, Room 7B

Session 732. Clinical Allogeneic Transplantation: Results: To Transplant or Not to Transplant? That Is the Question
206 A Personalized Prediction Model for Outcomes After Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee
Presenter: Aziz Nazha, MD
Co-Authors: Betty K. Hamilton, MD; Navneet S. Majhail, MD, MS; Ronald Sobecks, MD
2:15 p.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom A

207 Survival Differences Among Patients with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study
Co-Authors: Aaron T. Gerds, MD, MS; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MP
2:30 p.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom A

Sunday, Dec. 2
Session 732. Clinical Allogeneic Transplantation: Results: Optimizing Outcomes After Allogeneic Transplantation
308 Related and Unrelated Donor Transplantation for β Thalassemia Major: Results of an International Survey
Co-Author: Rabi Hanna, MD
7:45 a.m.
Manchester Grand Hyatt San Diego, Grand Hall A

Session 113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Sickle Cell Disease—Role of Coagulation and Inflammation in Pathophysiology
268 High Molecular Weight Kininogen Contributes to End-Organ Damage and Mortality in a Mouse Model of Sickle Cell Disease
Co-Author: Keith R. McCrae, MD
8:15 a.m.
San Diego Convention Center, Room 33B

Session 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: Combination Therapy
331 Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative and Subgroup Analyses Clinically Relevant Abstract
Co-Author: Anjali S. Advani, MD
9:30 a.m.
Manchester Grand Hyatt San Diego, Grand Hall B

Session 634. Myeloproliferative Syndromes: Clinical: Addressing Areas of Unmet Need in Prognostic Assessments and Therapy for MPNs
353 A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis
Co-Author: Aaron T. Gerds, MD, MS
10:30 a.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom F

Session 904. Outcomes Research—Malignant Conditions: Outcomes in Myeloid Malignancies and Allogeneic Stem Cell Transplant
371 Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States
Presenter: Raffi Tchekmedyian, BS
Co-Authors: Tomas Radivoyevitch, PhD; Aaron T. Gerds, MD, MS; Aziz Nazha; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Jaroslaw P. Maciejewski; Matt Kalaycio, MD; Navneet S. Majhail, MD, MS; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH
10:30 a.m.
San Diego Convention Center, Room 25B

Session 901. Health Services Research—Non-Malignant Conditions: Thrombosis and Anticoagulation
366 Economic Burden of Venous Thromboembolism in Cancer Patients — a Comparative Analysis Between Matched Patients with Cancer with and without a Diagnosis of Venous Thromboembolism
Co-Author: Alok A. Khorana, MD
10:45 a.m.
San Diego Convention Center, Room 8

Session 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: New Agents
397 Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study
Co-Authors: Deepa Jagadeesh, MD, MPH; Robert M. Dean, MD; Brad Pohlman, MD; Sarah L. Ondrejka, DO; Eric D. Hsi, MD; Brian T. Hill, MD, PhD
Noon
Marriott Marquis San Diego Marina, Pacific Ballroom 20

Session 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Population Based Outcomes in Aggressive Lymphoma
451 Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 U.S. Academic Centers
Co-Authors: Sarah S. Lee, MD; Brian T. Hill, MD, PhD
4:30 p.m.
San Diego Convention Center, Ballroom 20D

453 Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy
Co-Author: Brian T. Hill, MD, PhD
5 p.m.
San Diego Convention Center, Ballroom 20D

455 Outcomes of Patients with Relapsed/Refractory Double Expressor B Cell Lymphoma as Defined by Multicenter Pathology Review Treated with Ibrutinib Monotherapy
Co-Authors: Allison M. Winter, MD; Brian T. Hill, MD, PhD; Sarah L. Ondrejka, DO; Eric D. Hsi, MD 5:30 p.m.
San Diego Convention Center, Ballroom 20D

Session 637. Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics II
466 PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: an Initial Safety and Efficacy Analysis
Presenter: Aaron T. Gerds, MD, MS
5:15 p.m.
Manchester Grand Hyatt San Diego, Grand Hall A

Session 332. Antithrombotic Therapy: Management of Challenging Patients and Scenarios
425 Heparin vs Direct Thrombin Inhibitors in Patients with Previous HIT Undergoing Cardiothoracic Surgery: the Cleveland Clinic Experience
Presenter: Daniel S. Carlson, DO
Co-Author: Keith R. McCrae, MD
5:30 p.m.
San Diego Convention Center, Room 33B

Monday, Dec. 3
Session 634. Myeloproliferative Syndromes: Clinical: Interferon Therapy and Mutational Analysis in the MPNs
Moderator: Aaron T. Gerds, MD, MS
7:00–8:30 a.m.
Manchester Grand Hyatt San Diego, Grand Hall D

Session 508. Bone Marrow Failure: Acquired Bone Marrow Failure and Somatic Genetics
537 Next-Generation Sequencing Reveals a T Cell Receptor Signature Characteristic of Patients with Aplastic Anemia
Co-Authors: Cassandra M. Hirsch; Jaroslaw P. Maciejewski, MD, PhD
7:30 a.m.
Marriott Marquis San Diego Marina, Grand Ballroom 2

Session 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, Including HIV and Other Infections: B and T Cell Biology
516 Polyclonal Immune Response in T-LGL Leads to Clonal Expansions Preceding Occurrence of STAT3 Mutations Further Solidifying Clonal Dominance
Presenter: Cassandra M. Hirsch
Co-Authors: Michael Clemente, MS; Peter Chomczynski; Bartlomiej P. Przychodzen; Yasunobu Nagata; Vera Adema, PhD; Louis Williams, MD, MBA; Valeria Visconte, PhD; Alan Lichtin, MD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD
8:15 a.m.
San Diego Convention Center, Room 8

Session 703. Adoptive Immunotherapy: In Vitro, Correlative, and Early Phase Studies to Improve Safety and Efficacy of CAR-T Cells
697 Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR
Co-Author: Robert M. Dean, MD
10:30 a.m.
Marriott Marquis San Diego Marina, San Diego Ballroom B

Session 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Therapy of Post-Transplantation Relapse
704 Tyrosine Kinase Inhibitors with or without Donor Lymphocyte Infusion Continue to Provide Long-Term Survival After Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation
Co-Author: Ronald Sobecks, MD
10:45 a.m.
Manchester Grand Hyatt San Diego, Grand Hall B

Session 902. Health Services Research—Malignant Diseases: Big Data and Outcomes Research
712 Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety
Presenter: Madeline Waldron, PharmD
Co-Authors: Caitlin Siebenaller, PharmD; Marc Earl, PharmD; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Aziz Nazha, MD; Aaron T. Gerds, MD, MS; Betty K. Hamilton, MD; Ronald Sobecks, MD; Matt Kalaycio, MD; Barb Tripp, CNS; Brian P. Hobbs, PhD; Sudipto Mukherjee, MD, PhD, MPH; and Mikkael A. Sekeres, MD, MS
11:15 a.m.
San Diego Convention Center, Room 24B

Advertising Policy

Session 637. Myelodysplastic Syndromes—Clinical Studies: Prognosis and Prediction
793 A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes
Presenter: Aziz Nazha, MD
Co-Authors: Sudipto Mukherjee, MD, PhD, MPH; Yazan F. Madanat, MD; Teodora Kuzmanovic; Cassandra M. Hirsch; Vera Adema, PhD; Jaroslaw P. Maciejewski; Mikkael A. Sekeres, MD, MS
2:45 p.m.
Manchester Grand Hyatt San Diego, Grand Hall A

Session 902. Health Services Research—Malignant Diseases: Population Studies, End-of-life and Palliative Care
Moderator: Navneet S. Majhail, MD, MS
2:45–4:15 p.m.
San Diego Convention Center, Room 24B

Session 902. Health Services Research—Malignant Diseases: Quality Of Life Studies
Moderator: Betty K. Hamilton, MD
4:30–6:00 p.m.
San Diego Convention Center, Room 24B
Session 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches

929 Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach
Co-Author: Eric D. Hsi, MD
5:30 p.m.
San Diego Convention Center, Room 6F

Session 612. Acute Lymphoblastic Leukemia: Clinical Studies: Improving Outcomes with Cellular Therapy
900 Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?
Presenter: Remco J. Molenaar, MD, PhD
Co-Authors: Tomas Radivoyevitch; Aaron T. Gerds, MD, MS; Aziz Nazha, MD; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Matt Kalaycio, MD; Navneet S. Majhail, MD, MS; Jaroslaw P. Maciejewski; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH
5:45 p.m.
San Diego Convention Center, Room 6A

Session 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity and Novel Approaches with Targeted Therapy
1015 T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes
Co-Authors: Sagar S. Patel, MD
6:15 p.m.
Manchester Grand Hyatt San Diego, Seaport Ballroom A

Poster Sessions
Saturday, Dec. 1
6:15–8:15 p.m.
San Diego Convention Center, Hall GH

Session 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster I
1038 Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry
Co-Author: Jaroslaw P. Maciejewski

Session 112. Thalassemia and Globin Gene Regulation: Poster I
1054 The LSD1 Inhibitor RN-1 Increases Gamma-Globin Expression in Baboons by Targeting an Early Event Responsible for Gamma-Globin Repression
Co-Author: Yogenthiran Saunthararajah, MD

Session 331. Pathophysiology of Thrombosis: Poster I
1226 Expression of Recombinant β2GPI and Site-Directed Mutants Provides Insight into the Pathogenesis of Antiphospholipid Syndrome
Presenter: Ravi Kumar Alluri, PhD
Co-Authors: Suman Kundu, MBA; Keith R. McCrae, MD

Session 332. Antithrombotic Therapy: Poster I
1237 Clinical Outcomes with Direct Oral Anticoagulants Compared to Low Molecular Weight Heparins in the Treatment of Cancer-Associated Venous Thromboembolism
Presenter: Deborah Y. Park, BS
Co-Authors: Shyam K. Poudel, MD; Xuefei Jia, MS; Mailey Lynn Wilks, CNP, MSN, APRN; Vicki Pinkava, MSBS, PA-C; Meghan O’Brien, MS, ANP-BC; Barbara Tripp, CNS, AOCN; Jung-Min Song, RN, CNS; Keith R. McCrae, MD; Dana E. Angelini, MD; Alok A. Khorana, MD

1242 Outcomes Associated with Therapeutic Anticoagulation in Patients with Brain Metastasis
Presenter: Shafia Rahman, MD,
Co-Authors: Fahrettin Covut, MD, Yihong Zhou, MD, Shab E Gul Rahim, MD, Sudha Amarnath, MD, Alok A. Khorana, MD

Session 508. Bone Marrow Failure: Poster I
1302 Novel Small Molecule Stimulants of Hematopoietic Stem Cells and Their Mode of Action
Presenter: Sergei Vatolin, PhD
Co-Author: Jaroslaw P. Maciejewski, MD, PhD

1303 Selective Pharmacologic Inhibition of Paroxysmal Nocturnal Hemoglobinuria Clones
Presenter: Amy C. Graham, BS, MS
Co-Authors: Alexey Efanov, PhD; Bartlomiej P. Przychodzen; Cassandra M. Hirsch; Vera Adema, PhD; Valeria Visconte, PhD; Jaroslaw P. Maciejewski, MD, PhD

Session 613. Acute Myeloid Leukemia: Clinical Studies: Poster I
1388 Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: a Large Multi-Center Prospective Longitudinal Observational Study
Co-Authors: Aaron T. Gerds, MD, MS; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH

1389 Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations After Intensive Chemotherapy
Co-Authors: Bhumika J. Patel, MD; Hetty E. Carraway, MD, MBA; Teodora Kuzmanovic; Aziz Nazha, MD; Shimoli Vipul Barot, MD; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Sudipto Mukherjee, MD, PhD, MPH; Meghan Scully, NP; Aaron T. Gerds, MD, MS; Anjali S. Advani, MD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

Session 615. Acute Myeloid Leukemia: Commercially Available Therapy, Excluding Transplantation: Poster I
1428 Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: an Analysis from a Large International Patient Cohort
Co-Authors: Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH

Session 617. Acute Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster I
1491 Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group
Co-Authors: Heesun J. Rogers, MD, PhD; Eric D. Hsi, MD

1527 Differences in Genomic Patterns Between African Americans and Whites with Acute Myeloid Leukemia
Presenter: Rachel Hu, MD
Co-Authors: Aziz Nazha, MD;  Xuefei Jia, MS; Brian P. Hobbs, PhD; Hetty E. Carraway, MD, MBA; Sudipto Mukherjee, MD, PhD, MPH; Aaron T. Gerds, MD, MS; Anjali S. Advani, MD; Yasunobu Nagata; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Babal K. Jha; Jaroslaw P. Maciejewski, MD, PhD; Mikkael A. Sekeres, MD, MS

Session 622. Lymphoma Biology—Non-Genetic Studies: Poster I
1591 The Role of High Molecular Weight Kininogen in Lymphoma Microvascular Density and Growth
Presenter: Huseyin Halil Erdemir, MD
Co-Authors: Meenal Shukla, PhD; Keith R. McCrae, MD

Session 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I
1648 Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration
Co-Authors: Allison M. Winter, MD; Brian T. Hill, MD, PhD

Session 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I
1677 Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study
Co-Author: Brian T. Hill, MD, PhD

1692 Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Presenter: Brian T. Hill, MD, PhD
Co-Authors: Robert M. Dean, MD; Deepa Jagadeesh, MD, MPH; Alex V. Mejia Garcia, MD; Brad Pohlman, MD; Allison M. Winter, MD; Patrick Collier, MD, PhD; Christopher D’Andrea, PA-C; Ashley Morrison, RN; Sarah Lehmann, RN; Sarah L. Ondrejka, DO; Eric D. Hsi, MD

Session 632. Chronic Myeloid Leukemia: Therapy: Poster I
1737 Cardiovascular Mortality Among CML Patients in the Pre-TKI and TKI Eras: a SEER Analysis 1992–2004
Co-Author: Yaning Zhang, MD

Session 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I
1797 Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
Presenter: Yazan F. Madanat, MD
Co-Authors: Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH; Cassandra M. Hirsch; Yihong Guan; Yasunobu Nagata; Vera Adema, PhD; Metis Hasipek, PhD; Aaron T. Gerds, MD, MS; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Bartlomiej P. Przychodzen; Jaroslaw P. Maciejewski; Babal K. Jha; Aziz Nazha, MD

1801 Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data
Co-Author: Bartlomiej P. Przychodzen; Jaroslaw P. Maciejewski, MD, PhD

1802 Genetic Predisposition to Therapy-Related Myeloid Neoplasm by Rare, Deleterious Germline Variants in DNA Repair Pathway and Myeloid Driver Genes
Co-Authors: Cassandra M. Hirsch; Jaroslaw P. Maciejewski, MD, PhD

1805 Biallelic TET2 Inactivation in Myeloid Neoplasia: from Clonal Hierarchy to Clinical Phenotypes
Presenter: Hassan Awada, MD
Co-Authors: Yasunobu Nagata; Abhinav Goyal; Mohammad Fahad B. Asad; Bhumika J. Patel, MD; Cassandra M. Hirsch; Teodora Kuzmanovic; Vera Adema, PhD; Mai Aly; Bartlomiej P. Przychodzen; Yihong Guan; Louis Williams, MD, MBA; Aziz Nazha, MD; Mohamed Abazeed, MD, PhD; Mikkael A. Sekeres, MD, MS; Tomas Radivoyevitch; Babal K. Jha; Valeria Visconte, PhD; Jaroslaw P. Maciejewski, MD, PhD

Session 637. Myelodysplastic Syndromes—Clinical Studies: Poster I
1813 Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)
Presenter: C. Beau Hilton, BA
Co-Authors: Mikkael A. Sekeres, MD, MS; Aaron T. Gerds, MD, MS; Yihong Guan; Sudipto Mukherjee, MD, PhD, MPH; Yasunobu Nagata; Metis Hasipek, PhD; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Babal K. Jha; Jaroslaw P. Maciejewski, MD, PhD; Aziz Nazha, MD

1824 Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS)
Presenter: Yasunobu Nagata
Co-Authors: Abhinav Goyal; Inom Mirzaev; Mohammad Fahad B. Asad; Hassan Awada, MD; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Aziz Nazha, MD; Sudipto Mukherjee, MD, PhD, MPH; Mikkael A. Sekeres, MD, MS; Tomas Radivoyevitch, PhD; Jacob Scott, MD; Jaroslaw P. Maciejewski, MD, PhD

1825 Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey
Co-Author: Mikkael A. Sekeres, MD, MS

Session 651. Myeloma: Biology and Pathophysiology, Excluding Therapy: Poster I
1899 Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma
Presenter: Rajshekhar Chakraborty, MBBS
Co-Authors: Lisa Rybicki, MS; Robert M. Dean, MD; Beth M. Faiman, PhD, CNP; Matt Kalaycio, MD; Jack Khouri, MD; Christy J. Samaras, DO; Navneet S. Majhail, MD, MS; Jason Valent, MD

Session 653. Myeloma: Therapy, Excluding Transplantation: Poster I
1948 Efficacy and Toxicity Profile of Ibrutinib Based Regimens for Refractory Multiple Myeloma: A Systematic Review
Co-Author: Faiz Anwer, MD

1949 Promising Clinical Efficacy and Toxicity Profile of Isatuximab Based Regimens for Treatment of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: A Systematic Review
Co-Author: Faiz Anwer, MD

1950 Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: a Systematic Review of Early Clinical Data
Co-Author: Faiz Anwer, MD

1951 Presentation Patterns and Management Strategies for Central Nervous System Involvement in Multiple Myeloma: a Systematic Review of Literature
Co-Author: Faiz Anwer, MD

1952 Evidence Based Recommendations for Supportive Care in Multiple Myeloma
Co-Author: Faiz Anwer, MD

1962 Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide
Co-Author: Jason Valent, MD

2009 Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis
Presenter: Sarah S. Lee, MD
Co-Author: Nathaniel Rosko, PharmD; Bhumika J. Patel, MD; Madeline Waldron, PharmD; Jackie Tomer, MPH; Roman Goldman, CNP; Mary Ann Karam, RN; Janice Reed, RN; Beth M. Faiman, PhD, CNP; Kimberly Hamilton, APRN/PA; Saveta Mathur, CNP; Christy J. Samaras, DO; and Jason Valent, MD

2012 Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
Co-Author: Christy J. Samaras, DO

2022 Pomalidomide Based Regimens for Treatment of Relapsed Multiple Myeloma: a Systematic Review and Meta-Analysis of Clinical Trials
Co-Author: Faiz Anwer, MD

2025 Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: a Systematic Review
Co-Author: Faiz Anwer, MD

Session 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Poster I
2075 Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia
Presenter: Sagar S. Patel, MD
Co-Authors: Betty K. Hamilton, MD; Lisa Rybicki, MS; Dawn Thomas; Arden Emrick; Aziz Nazha; Sudipto Mukherjee, MD, PhD, MPH; Anjali S. Advani, MD; Hetty E. Carraway, MD, MBA; Brad Pohlman, MD; Brian J. Bolwell, MD; Robert M. Dean, MD; Aaron T. Gerds, MD, MS; Rabi Hanna, MD; Matt Kalaycio, MD; Aiwen Zhang, PhD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD; Navneet S. Majhail, MD, MS; Ronald Sobecks, MD

Session 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
2123 Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution After Nicotinamide-Expanded Cord Blood Transplantation
Co-Author: Rabi Hanna, MD

Session 801. Gene Therapy and Transfer: Poster I
2194 Gene Therapy for Thalassemia and Sickle Cell Anemia Poses Acceptable Toxicity and Efficacy: Clinical Outcomes in Forty-Seven Cases
Co-Author: Faiz Anwer, MD

Session 902. Health Services Research—Malignant Diseases: Poster I
2245 Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: a Systematic Review with a Specific Focus on Geriatric Population
Co-Author: Navneet S. Majhail, MD, MS

2246 Qualitative Study of Factors that Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia
Co-Author: Navneet S. Majhail, MD, MS

2259 Correlation Between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal Study
Co-Author: Aaron T. Gerds, MD, MS

2270 TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer
Presenter: Sophia Colombari Figueroa, BA
Co-Authors: Bhumika J. Patel, MD; Shimoli Vipul Barot, MD; Teodora Kuzmanovic, BA; Aziz Nazha, MD; Eric D. Hsi, MD; James R. Cook, MD, PhD; Sudipto Mukherjee, MD, PhD, MPH; Aaron T. Gerds, MD, MS; Mikkael A. Sekeres, MD, MS; Matt Kalaycio, MD; Anjali S. Advani, MD; Jaroslaw P. Maciejewski, MD, PhD; Hetty E. Carraway, MD, MBA

Session 904. Outcomes Research—Malignant Conditions: Poster I
2298 Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States
Presenter: Raffi Tchekmedyian, BS
Co-Authors: Tomas Radivoyevitch, PhD; Aaron T. Gerds, MD, MS; Aziz Nazha, MD; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Jaroslaw P. Maciejewski, MD, PhD; Matt Kalaycio, MD; Navneet S. Majhail, MD, MS; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH

Sunday, Dec. 2
6–8 p.m.
San Diego Convention Center, Hall GH
Session 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II
2330 A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria
Co-Author: Jaroslaw P. Maciejewski, MD, PhD

Session 331. Pathophysiology of Thrombosis: Poster II
2510 Venous Thromboembolism in Cancer Patients Receiving Immunotherapy
Presenter: Joanna Roopkumar, MBBS, MPH
Co-Authors: Ann S. Kim, BA; Thapa Bicky, MD; Brian P. Hobbs, PhD; Alok A. Khorana, MD

Session 503. Clonal Hematopoiesis: Aging and Inflammation: Poster II
2572 Distinct Features of Chip-Derived and De Novo MDS
Presenter: Yasunobu Nagata
Co-Authors: Cassandra M. Hirsch; Hassan Awada, MD; Abhinav Goyal; Teodora Kuzmanovic, BA; Bartlomiej P. Przychodzen; Sudipto Mukherjee, MD, PhD, MPH; Tomas Radivoyevitch, PhD; Aziz Nazha, MD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

Session 508. Bone Marrow Failure: Poster II
2583 Pathogenic Germline Variants in Acquired Aplastic Anemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH)
Co-Authors: Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Sudipto Mukherjee, MD, PhD, MPH; Hetty E. Carraway, MD, MBA; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

2590 Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia
Presenter: Bhumika J. Patel, MD
Co-Authors: Shimoli Vipul Barot, MD; Teodora Kuzmanovic, BA; Bartlomiej P. Przychodzen; Cassandra M. Hirsch; Hassan Awada, MD; Metis Hasipek, PhD; Swapna Thota, MD; Tomas Radivoyevitch, PhD; Anjali S. Advani, MD; Matt Kalaycio, MD; Mikkael A. Sekeres, MD, MS; Hetty E. Carraway, MD, MBA; Jaroslaw P. Maciejewski, MD, PhD

Session 614. Acute Lymphoblastic Leukemia: Therapy, Excluding Transplantation: Poster II
2699 Comparison of CD22 Expression Between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials
Co-Author: Anjali S. Advani, MD

Session 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: Poster II
2732 Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib ‘On Target’ Adverse Events
Co-Author: Mikkael A. Sekeres, MD, MS

2735 Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Co-Author: Mikkael A. Sekeres, MD, MS

Session 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II
2809 Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype
Presenter: Aziz Nazha, MD
Co-Authors: Sudipto Mukherjee, MD, PhD, MPH; Ahed Makhoul, MD; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Hetty E. Carraway, MD, MBA; Yasunobu Nagata; Yihong Guan; Teodora Kuzmanovic, BA; Metis Hasipek, PhD; Babal K. Jha; Jaroslaw P. Maciejewski, MD, PhD; Mikkael A. Sekeres, MD, MS

Session 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II
2878 Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration
Co-Author: Eric D. Hsi, MD

2893 Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies
Co-Author: Deepa Jagadeesh, MD, MPH

Advertising Policy

Session 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II

2927 Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: a Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis
Co-Author: Eric D. Hsi, MD

Session 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster II

2967 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Co-Author: Brian T. Hill, MD, PhD

Session 634. Myeloproliferative Syndromes: Clinical: Poster II
3027 Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)
Co-Author: Aaron T. Gerds, MD, MS

Session 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II
3073 LUC7L2 Is a Novel RNA-Splicing Regulatory Factor Mutated in Myelodysplastic Syndromes
Presenter: Courtney Hershberger, BS
Co-Authors: James Hiznay; Rosemary Dietrich; Xiaorong Gu, PhD; Cassandra M. Hirsch; Amy Graham, BS, MS; Bartlomiej P. Przychodzen; Valeria Visconte, PhD; Vera Adema, PhD; Yvonne Parker; Hetty E. Carraway, MD, MBA; Tomas Radivoyevitch, PhD; Mikkael A. Sekeres, MD, MS; Yogen Saunthararajah, MD; Jaroslaw P. Maciejewski, MD, PhD; Richard A. Padgett

3074 Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS
Presenter: Cassandra M. Hirsch
Co-Authors: Wenyi Shen, MD; Bartlomiej P. Przychodzen; Yasunobu Nagata; Vera Adema, PhD; Teodora Kuzmanovic, BA; Louis Williams, MD, MBA; Aziz Nazha, MD; Valeria Visconte, PhD; Hetty E. Carraway, MD, MBA; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

3084 Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced by Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential
Presenter: Teodora Kuzmanovic
Co-Authors: Bhumika J. Patel, MD; Yasunobu Nagata; Hassan Awada, MD; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Remco J. Molenaar, MD, PhD; Babal K. Jha; Sudipto Mukherjee, MD, PhD, MPH; Anjali S. Advani, MD; Aziz Nazha, MD; Aaron T. Gerds, MD, MS; Hetty E. Carraway, MD, MBA; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD; Tomas Radivoyevitch, PhD

Session 637. Myelodysplastic Syndromes—Clinical Studies: Poster II
3091 Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Co-Author: Mikkael A. Sekeres, MD, MS

3095 Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA
Presenter: Sudipto Mukherjee, MD, PhD, MPH
Co-Authors: Tomas Radivoyevitch, PhD; Brian P. Hobbs, PhD; Xuefei Jia, MS; Jaroslaw P. Maciejewski, MD, PhD; Aziz Nazha, MD; Mikkael A. Sekeres, MD, MS

3096 Does Trial Participation Improve Outcomes for Higher-Risk Myelodysplastic Syndromes (MDS) Patients Treated at Specialty Centers?
Presenter: Sudipto Mukherjee, MD, PhD, MPH
Co-Authors: Aziz Nazha; Jaroslaw P. Maciejewski, MD, PhD; Mikkael A. Sekeres, MD, MS; Brian P. Hobbs, PhD; Xuefei Jia, MS

3098 What Is the Optimal Time to Initiate Hypomethylating Agents (HMA) in Higher Risk Myelodysplastic Syndromes (MDS)?
Co-Authors: Aziz Nazha, MD; Mikkael A. Sekeres, MD, MS

3103 Therapy-Related MDS Can Be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS
Co-Author: Mikkael A. Sekeres, MD, MS

Session 642. CLL: Therapy, Excluding Transplantation: Poster II
3142 Venetoclax as Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients
Co-Authors: Brian T. Hill, MD, PhD; Allison M. Winter, MD

Session 653. Myeloma: Therapy, Excluding Transplantation: Poster II
3239 Efficacy of Lenalidomide Based Three Drug Versus Two Drug Regimen for Relapsed Multiple Myeloma: a Systematic Review and Meta-Analysis of Randomized Trials
Co-Author: Faiz Anwer, MD

3271 Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma After Lenalidomide-Based Treatment Failure
Co-Author: Christy J. Samaras, DO

3292 Efficacy and Safety of Daratumumab Based Regimens for Multiple Myeloma: a Systematic Review and Meta-Analysis
Co-Author: Faiz Anwer, MD

3309 Presentation Pattern, Diagnostic Markers, Management and Outcome of IgD Multiple Myeloma: a Systematic Review
Co-Author: Faiz Anwer, MD

Session 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II

3365 Comparative Effectiveness of Busulfan/Cyclophosphamide Versus Busulfan/Fludarabine Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia
Presenter: Sagar S. Patel, MD
Co-Authors: Lisa Rybicki, MS; Arden Emrick; Victoria Winslow, RN; Jamie Starn, RN; Jamie Elberson, RN; Brittany Hodgeman, RN; Brad Pohlman, MD; Brian J. Bolwell, MD; Aaron T. Gerds, MD, MS; Betty K. Hamilton, MD; Rabi Hanna, MD; Matt Kalaycio, MD; Navneet S. Majhail, MD, MS; Ronald Sobecks, MD

Session 902. Health Services Research—Malignant Diseases: Poster II

3562 The Healthcare Burden of Emergency Department Utilization for Multiple Myeloma: a Five Years U.S Nationwide Study
Co-Author: Faiz Anwer, MD

Session 903. Outcomes Research—Non-Malignant Hematology: Poster II
3570 Deaths Due to Thrombotic Versus Bleeding Events Within 90 Days of Cancer Associated Thrombosis
Presenter: Mailey L. Wilks, MSN, APRN, NP-C
Co-Authors: Shyam K. Poudel, MD; Deborah Y. Park, BS; Xuefei Jia, MS; Vicki Pinkava, MSBS, PA-C; Meghan O’Brien, MS, ANP-BC; Barb Tripp, CNS; Jung-Min Song, RN, CNS; Keith R. McCrae, MD; Alok A. Khorana, MD; Dana E. Angelini, MD

Session 904. Outcomes Research—Malignant Conditions: Poster II
3600 Psychosocial Evaluation in Allogeneic Hematopoietic Cell Transplantation Recipients (Allo HCT): Psychosocial Assessment of Candidates for Transplant (PACT) as a Tool to Identify High-Risk Patients and Its Association with Transplant Outcomes
Co-Authors: Lisa Rybicki, MS; Jane Dabney, LISW-S; Christine Lawrence, LISW-S; Betty K. Hamilton, MD; Matt Kalaycio, MD; Linda McLellan, LISW; Ronald Sobecks, MD; Navneet S. Majhail, MD, MS

Monday, Dec. 3
6–8 p.m.
San Diego Convention Center, Hall GH
Session 331. Pathophysiology of Thrombosis: Poster III
3798 The Rate of Venous Thromboembolism in Cancer Patients Varies by Khorana Risk Category
Presenter: Alok A. Khorana, MD
Co-Author: Keith R. McCrae, MD

3799 Healthcare Costs in Patients with Cancer Increase with Increasing Risk of Venous Thromboembolism
Co-Authors: Keith R. McCrae, MD; Alok A. Khorana, MD
3800 Exosome Polyphosphate Mediates the Activation of FXII by Cancer Cell-Derived Exosomes
Presenter: Dewen You, PhD
Co-Authors: Suman Kundu, MBA; Alvin H. Schmaier, MD; Alok A. Khorana, MD; Keith R. McCrae, MD

Session 503. Clonal Hematopoiesis: Aging and Inflammation: Poster III
3840 Targeting NAD+ Modulating Enzymes to Improve HSC Function in Aging and Bone Marrow Failure
Presenter: Phillip J. Maciejewski
Co-Authors: Yihong Guan; Metis Hasipek, PhD; Anand D. Tiwari, PhD; Dale Grabowski, BS; James G. Phillips, PhD; Yogenthiran Saunthararajah, MD; Jaroslaw P. Maciejewski; Babal K. Jha

Session 508. Bone Marrow Failure: Poster III
3866 Heterozygous CTC1 Variants in Acquired Bone Marrow Failure
Presenter: Wenyi Shen, MD
Co-Authors: Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Reda Z. Mahfouz, MD, PhD; Tomas Radivoyevitch; Mohammad Fahad B. Asad; Jaroslaw P. Maciejewski, MD, PhD

3869 Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia
Presenter: Bhumika J. Patel, MD
Co-Authors: Shimoli Vipul Barot, MD; Bartlomiej P. Przychodzen; Teodora Kuzmanovic, BA; Michael Clemente, MS; Cassandra M. Hirsch; Valeria Visconte, PhD; Roy Souaid, MD; Marissa Versalle; Sarah S. Lee, MD; Tomas Radivoyevitch; Metis Haspiek; Aziz Nazha, MD; Matt Kalaycio, MD; Anjali S. Advani, MD; Hetty E. Carraway, MD, MBA; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

3871 The Shwachman-Diamond Syndrome Registry: Hematologic Complications
Co-Author: Rabi Hanna, MD

Session 613. Acute Myeloid Leukemia: Clinical Studies: Poster III
3999 Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database
Co-Authors: Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH

Session 614. Acute Lymphoblastic Leukemia: Therapy, Excluding Transplantation: Poster III
4031 Exploration of Potential Relationships Between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study
Co-Author: Anjali S. Advani, MD

Session 615. Acute Myeloid Leukemia: Commercially Available Therapy, Excluding Transplantation: Poster III
4040 Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort
Co-Authors: Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH

Session 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: Poster III

4067 Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia
Presenter: Metis Hasipek, PhD
Co-Authors: Dale Grabowski, BS; Yihong Guan; James G. Phillips, PhD; Jaroslaw P. Maciejewski, MD, PhD; Hetty E. Carraway, MD, MBA; Babal K. Jha

Session 623. Mantle Cell, Follicular and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
4146 Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival
Presenter: Allison M. Winter, MD
Co-Authors: Dhruvika Mukhija, MD; Deepa Jagadeesh, MD, MPH; Brian T. Hill, MD, PhD

4153 Intensive Induction Regimens After Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL)
Co-Authors: Yazeed Sawalha, MD; Brian T. Hill, MD, PhD

Session 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster III
4202 Risk of Post-Transplant Lymphoproliferative Disorders (PTLD) in Solid Organ Transplantation Patients with EBV Viremia
Presenter: Yazeed Sawalha, MD
Co-Authors: John McMichael, PhD; Lisa Rybicki, MS; Tamara A. Sussman, MD; Alex V. Mejia Garcia, MD; Robert M. Dean, MD; Brad Pohlman, MD; Brian T. Hill, MD, PhD; Deepa Jagadeesh, MD, MPH

Session 632. Chronic Myeloid Leukemia: Therapy: Poster III
4274 Poisson Regression Modeling of Chronic Myeloid Leukemia Mortality Trends
Presenter: Tomas Radivoyevitch
Co-Authors: Brian P. Hobbs, PhD; Jaroslaw P. Maciejewski, MD, PhD

Session 634. Myeloproliferative Syndromes: Clinical: Poster III
4282 Hepcidin Suppression by Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients
Co-Author: Aaron T. Gerds, MD, MS

4288 Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score
Co-Authors: Aaron T. Gerds, MD, MS; Ronald Sobecks, MD

Session 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III
4345 Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases
Presenter: Yihong Guan
Co-Authors: Anand D. Tiwari, PhD; Metis Hasipek, PhD; Dale Grabowski, BS; Yvonne Parker; Cassandra M. Hirsch; Amy C. Graham, BS, MS; Yasunobu Nagata; Bartlomiej P. Przychodzen; Aziz Nazha, MD; Daniel Lindner, MD, PhD; Tomas Radivoyevitch, PhD; James G. Phillips, PhD; Jaroslaw P. Maciejewski, MD, PhD; Babal K. Jha

4346 Modulation of TET2 Activity by Ascorbic Acid and Factors Affecting Lysine Acetylation
Presenter: Yihong Guan
Co-Authors: Edward F. Greenberg, MD; Metis Hasipek, PhD; Cassandra M. Hirsch; Amy C. Graham, BS, MS; Tomas Radivoyevitch, PhD; Valeria Visconte, PhD; Dewen You, PhD; Eiju Negoro, MD, PhD; Bartlomiej P. Przychodzen; Hideki Makishima, MD, PhD; Aziz Nazha, MD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD; Babal K. Jha

4350 SKI Controls MDS-Associated Chronic TGFb Signaling, Aberrant Splicing, and Stem Cell Fitness
Co-Author: Clemencia Colmenares, PhD
4351 Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS)
Presenter: Yasunobu Nagata
Co-Authors: Yihong Guan; Bartlomiej P. Przychodzen; Cassandra M. Hirsch; Teodora Kuzmanovic, BA; Tomas Radivoyevitch, PhD; Vera Adema, PhD; Hassan Awada, MD; Babal K. Jha; Rabi Hanna, MD; Thomas Laframboise, PhD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

4352 BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden
Co-Authors: Teodora Kuzmanovic, BA; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Yogenthiran Saunthararajah, MD; Hassan Awada, MD; Vera Adema, PhD; Amy C. Graham, BS, MS; Tomas Radivoyevitch, PhD; Hetty E. Carraway, MD, MBA; Aziz Nazha; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

4353 Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML
Presenter: Teodora Kuzmanovic
Co-Authors: Bhumika J. Patel, MD; Yasunobu Nagata; Hassan Awada, MD; Cassandra M. Hirsch; Bartlomiej P. Przychodzen; Sudipto Mukherjee, MD, PhD, MPH; Anjali S. Advani, MD; Aziz Nazha, MD; Aaron T. Gerds, MD, MS; Tomas Radivoyevitch, PhD; Hetty E. Carraway, MD, MBA; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD

Session 637. Myelodysplastic Syndromes—Clinical Studies: Poster III
4370 Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance Between Local and Central Review in the NHLBI MDS Natural History Study
Co-Author: Mikkael A. Sekeres, MD, MS

4374 Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes
Co-Authors: John Barnard, PhD; Mikkael A. Sekeres, MD, MS

4389 Molecular Spectrum of CSF3R Variants Correlate with Specific Myeloid Malignancies and Secondary Mutations
Presenter: Vera Adema, PhD
Co-Authors: Cassandra M. Hirsch; Bartlomiej Przychodzen; Yasunobu Nagata; Tomas Radivoyevitch; Amy C. Graham, BS, MS; Louis Williams, MD, MBA; Hassan Awada, MD; Aziz Nazha; Hetty E. Carraway, MD, MBA; Hrishikesh M. Mehta, PhD; Mikkael A. Sekeres, MD, MS; Valeria Visconte, PhD; Rabi Hanna, MD; Seth J. Corey, MD; Jaroslaw P. Maciejewski, MD, PhD

Session 641. CLL: Biology and Pathophysiology, Excluding Therapy: Poster III
4410 Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings
Co-Authors: Brian T. Hill, MD, PhD; Allison M. Winter, MD

4414 Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States
Co-Author: Brian T. Hill, MD, PhD

Session 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III
4603 Risk Factors for Early Relapse After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia
Presenter: Sagar S. Patel, MD
Co-Authors: Betty K. Hamilton, MD; Lisa Rybicki, MS; Dawn Thomas; Arden Emrick; Aziz Nazha; Sudipto Mukherjee, MD, PhD, MPH; Anjali S. Advani, MD; Hetty E. Carraway, MD, MBA; Brad Pohlman, MD; Brian J. Bolwell, MD; Robert M. Dean, MD; Aaron T. Gerds, MD, MS; Rabi Hanna, MD; Matt Kalaycio, MD; Aiwen Zhang, PhD; Mikkael A. Sekeres, MD, MS; Jaroslaw P. Maciejewski, MD, PhD; Navneet S. Majhail, MD, MS; Ronald Sobecks, MD

Session 901. Health Services Research—Non-Malignant Conditions: Poster III
4695 National Trends in Leukemia Related Emergency Department Visits, Health Care Burden and Disposition Rate in the United States, 2010-2014
Co-Author: Faiz Anwer, MD

Session 902. Health Services Research—Malignant Diseases: Poster III
4731 Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Disease Registry
Co-Author: Mikkael A. Sekeres, MD, MS

4736 Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect® MDS/AML Disease Registry
Presenter: Sudipto Mukherjee, MD, PhD, MPH

4755 Early Infectious Complications after Autologous Hematopoietic Cell Transplantation (AHCT) for Lymphoma
Presenter: Shafia Rahman, MD
Co-Authors: Lisa Rybicki, MS; Eric Cober, MD; Robert M. Dean, MD; Betty K. Hamilton, MD; Deepa Jagadeesh, MD, MPH; Brian T. Hill, MD, PhD; Brad Pohlman, MD; Ronald Sobecks, MD; Matt Kalaycio, MD; Sherif Mossad, MD; Navneet S. Majhail, MD

4759 Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: a Multicenter Study
Co-Authors: Brian T. Hill, MD, PhD; Allison M. Winter, MD

4768 Adolescent and Young Adult (AYA) Hematopoietic Cell Transplantation (HCT) Recipients Have Similar Quality of Life (QoL) Compared to Older Adults in the First Year Post-Transplantation
Presenter: Reema R. Mathanda, MD
Co-Authors: Betty K. Hamilton, MD; Lisa Rybicki, MS; Anjali S. Advani, MD; Brian J. Bolwell, MD; Amy Colver, LISW; Jane Dabney, LISW-S; Christina Ferraro, CNP; Aron Flagg, MD; Rabi Hanna, MD; Matt Kalaycio, MD; Christine Lawrence, LISW-S; Linda McLellan, LISW; Ronald Sobecks, MD; Navneet S. Majhail, MD, MS

4802 Cost and Value Analysis of Standard Versus Rapid Daratumumab Infusion in Multiple Myeloma
Presenter: Sarah S. Lee, MD
Co-Authors: Nathaniel Rosko, PharmD; Pramod Pinnamaneni, MD; Craig Savage; Alex V. Mejia Garcia, MD; Christy J. Samaras, DO; and Jason Valent, MD

Session 903. Outcomes Research—Non-Malignant Hematology: Poster III
4805 Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis
Presenter: Madeline Waldron, PharmD
Co-Authors: Caitlin Siebenaller, PharmD; Brian P. Hobbs, PhD; Marc Earl, PharmD; Mary Schleicher; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Aziz Nazha, MD; Aaron T. Gerds, MD, MS; Betty K. Hamilton, MD; Ronald Sobecks, MD; Matt Kalaycio, MD; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH

4806 Impact of Venous Thromboembolism During High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay
Presenter: Madeline Waldron, PharmD
Co-Authors: Caitlin Siebenaller, PharmD; Marc Earl, PharmD; Xuefei Jia, MS; Hetty E. Carraway, MD, MBA; Anjali S. Advani, MD; Aziz Nazha, MD; Aaron T. Gerds, MD, MS; Betty K. Hamilton, MD; Ronald Sobecks, MD; Matt Kalaycio, MD; Barb Tripp, CNS; Brian P. Hobbs, PhD; Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH

4809 Clinical Outcomes of Isolated Distal Deep Vein Thrombosis Associated with Cancer: the Cleveland Clinic Experience
Presenter: Shyam K. Poudel, MD
Co-Authors: Xuefei Jia, MS; Deborah Y. Park, BS; Mailey Lynn Wilks, CNP, MSN, APRN; Vicki Pinkava, MSBS, PA-C; Meghan O’Brien, MS, ANP-BC; Barbara Tripp, CNS, AOCN; Jung-Min Song, RN, CNS; Keith R. McCrae, MD; Alok A. Khorana, MD; Dana E. Angelini, MD

Session 904. Outcomes Research—Malignant Conditions: Poster III
4832 Patient-Reported Outcomes in Systemic Light-Chain Amyloidosis
Presenter: Rajshekhar Chakraborty, MBBS
Co-Authors: Lisa Rybicki, MS; Christy J. Samaras, DO; Beth M. Faiman, PhD, CNP; Jason Valent, MD; Navneet S. Majhail, MD, MS

4835 Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: a Systemic Review and Meta-Analysis
Presenter: Rajshekhar Chakraborty, MBBS
Co-Authors: Naimisha Marneni; Alex V. Mejia Garcia, MD; Faiz Anwer, MD; Alok A. Khorana, MD; Navneet S. Majhail, MD, MS